These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11192828)

  • 21. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.
    Köstler WJ; Schwab B; Singer CF; Neumann R; Rücklinger E; Brodowicz T; Tomek S; Niedermayr M; Hejna M; Steger GG; Krainer M; Wiltschke C; Zielinski CC
    Clin Cancer Res; 2004 Mar; 10(5):1618-24. PubMed ID: 15014012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.
    Molina R; Augé JM; Escudero JM; Filella X; Zanon G; Pahisa J; Farrus B; Muñoz M; Velasco M
    Tumour Biol; 2010 Jun; 31(3):171-80. PubMed ID: 20361287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
    Ali SM; Leitzel K; Chinchilli VM; Engle L; Demers L; Harvey HA; Carney W; Allard JW; Lipton A
    Clin Chem; 2002 Aug; 48(8):1314-20. PubMed ID: 12142389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
    Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer.
    Köstler WJ; Steger GG; Soleiman A; Schwab B; Singer CF; Tomek S; Brodowicz T; Krainer M; Wiltschke C; Horvat R; Jakesz R; Zielinski CC
    Anticancer Res; 2004; 24(2C):1127-30. PubMed ID: 15154635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
    Hudelist G; Köstler WJ; Gschwantler-Kaulich D; Czerwenka K; Kubista E; Müller R; Helmy S; Manavi M; Zielinski CC; Singer CF
    Eur J Cancer; 2006 Jan; 42(2):186-92. PubMed ID: 16326100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting response to herceptin therapy.
    Lipton A; Leitzel K; Ali S
    Clin Cancer Res; 2004 Mar; 10(5):1559-60. PubMed ID: 15014003
    [No Abstract]   [Full Text] [Related]  

  • 28. Her-2/neu and breast cancer.
    Kaptain S; Tan LK; Chen B
    Diagn Mol Pathol; 2001 Sep; 10(3):139-52. PubMed ID: 11552716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
    Dawood S; Broglio K; Buzdar AU; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2010 Jan; 28(1):92-8. PubMed ID: 19933921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor M2 pyruvate kinase--determination in breast cancer patients receiving trastuzumab therapy.
    Hoopmann M; Warm M; Mallmann P; Thomas A; Göhring UJ; Schöndorf T
    Cancer Lett; 2002 Dec; 187(1-2):223-8. PubMed ID: 12359372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER-2/neu expression in primary and metastatic breast cancer.
    Lower EE; Glass E; Blau R; Harman S
    Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients.
    Perez SA; Karamouzis MV; Skarlos DV; Ardavanis A; Sotiriadou NN; Iliopoulou EG; Salagianni ML; Orphanos G; Baxevanis CN; Rigatos G; Papamichail M
    Clin Cancer Res; 2007 May; 13(9):2714-21. PubMed ID: 17473204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.
    Köstler WJ; Brodowicz T; Hudelist G; Rudas M; Horvat R; Steger GG; Singer CF; Attems J; Rabitsch W; Fakhrai N; Elandt K; Wiltschke C; Hejna M; Zielinski CC
    J Cancer Res Clin Oncol; 2005 Jul; 131(7):420-8. PubMed ID: 15864644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay.
    Dittadi R; Zancan M; Perasole A; Gion M
    Int J Biol Markers; 2001; 16(4):255-61. PubMed ID: 11820721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer patients should not live without a HER-2/neu tissue result--but how safe can they live with it?
    Lüftner D
    Wien Klin Wochenschr; 2004 Jan; 116(1-2):3-5. PubMed ID: 15030116
    [No Abstract]   [Full Text] [Related]  

  • 37. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
    Lipton A; Ali SM; Leitzel K; Demers L; Chinchilli V; Engle L; Harvey HA; Brady C; Nalin CM; Dugan M; Carney W; Allard J
    J Clin Oncol; 2002 Mar; 20(6):1467-72. PubMed ID: 11896093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
    Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
    J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors.
    Papila C; Uzun H; Balci H; Zerdali H; Sezgin C; Can G; Yanardag H
    Med Oncol; 2009; 26(2):151-6. PubMed ID: 18855148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum HER-2/neu in the management of breast cancer patients.
    Lüftner D; Lüke C; Possinger K
    Clin Biochem; 2003 Jun; 36(4):233-40. PubMed ID: 12810150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.